Report from the Cardiovascular and Renal Drugs Advisory Committee: US Food and Drug Administration; June 15-16, 2005; Gaithersburg, Md.
Nissen
Steven E
SE
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA. nissens@ccf.org
D000959:Antihypertensive Agents / Q000627:therapeutic use; D044383:Black People; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D004348:Drug Labeling; D015991:Epidemiologic Measurements; D006333:Heart Failure / Q000188:drug therapy / Q000208:ethnology; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D009566:Nitrates / Q000627:therapeutic use; D010372:Pediatrics; D012076:Renal Agents / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D001741:Black or African American
D000959:Antihypertensive Agents; D002317:Cardiovascular Agents; D004338:Drug Combinations; D009566:Nitrates; D012076:Renal Agents; D006830:Hydralazine